58 reports of this reaction
1.8% of all PIOGLITAZONE HYDROCHLORIDE reports
#5 most reported adverse reaction
HYPOGLYCAEMIA is the #5 most commonly reported adverse reaction for PIOGLITAZONE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 58 FDA adverse event reports linking PIOGLITAZONE HYDROCHLORIDE to HYPOGLYCAEMIA. This represents approximately 1.8% of all 3,283 adverse event reports for this drug.
Patients taking PIOGLITAZONE HYDROCHLORIDE who experience hypoglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOGLYCAEMIA is a less commonly reported adverse event for PIOGLITAZONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hypoglycaemia, the following adverse reactions have been reported for PIOGLITAZONE HYDROCHLORIDE:
The following drugs have also been linked to hypoglycaemia in FDA adverse event reports:
HYPOGLYCAEMIA has been reported as an adverse event in 58 FDA reports for PIOGLITAZONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOGLYCAEMIA accounts for approximately 1.8% of all adverse event reports for PIOGLITAZONE HYDROCHLORIDE, making it a notable side effect.
If you experience hypoglycaemia while taking PIOGLITAZONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.